EXOZ

EXOZYMES INC.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. NV· CIK 0002010788 Biotech & Drug Discovery

$3.75 −0.25 (−6.25%)

Oct 26 4:00 PM ET · prev $4.00

Market cap

$36.3M

Nano cap

Next earnings

Nov 9

in 13 days

1 year

−69.7%

from $12.36 · Oct 27

30 days

−37.5%

from $6.00

52-week range

$3.75–16.50

at the low

Avg volume 20D

11.4K

Oct 16 spike 32.1K

Short interest

🔒 Subscribers only

Insider net

−$9.0K

12 mo · excl. 1 subscriber-only trade

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 4 reports · 90 days

Balance 0 bearish · 0 bullish · 4 neutral oldest → newest, height = score

Avg score

·High conf. 4/4 ·Next Earnings date, Nov 9, 2026

Strongest NEUTRAL eXoZymes Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on September 28, 2026, in…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Apr 8 to Apr 9 2 days of insider sells: $15.4K by 1 insider, avg $10.28
R Jun 4 EXOZ is conducting a dilutive public offering of common stock and wa…
R Jun 8 EXOZYMES INC. entered into an underwriting agreement on June 5, 2026…
R Jun 8 EXOZYMES INC. is raising approximately $4.7 million (before expenses…
R Jun 17 EXOZYMES INC. closed its underwritten public offering of common stoc…
R Jun 30 Exozymes is raising $565,206 net proceeds via a registered direct of…
B Aug 25 to Aug 26 2 days of insider buys: $6.4K by 1 insider, avg $7.49
E Oct 16 Trading halt: Halt Resumed: EXOZ — trading resumed after LUDP (Volatilit…

Signal stack

Where each data set points today.

InsidersMIXED

1 insider bought $6.4K at an average $7.49. 1 insider sold $15.4K. Price is 50% below their cost. Excludes 1 subscriber-only trade.
InstitutionsBULLISH

Q2 2026: 3 added (0 new), 0 trimmed or exited.
TrendDOWNTREND

36% below its 50-day average. New closing low $3.75 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	DOUBLED	54,985	$463.5K
BlackRock, Inc.	ADD	9,610	$81.0K
UBS Group AG	DOUBLED	203	$1.7K
UBS Group AG	DOUBLED	24	$180.00
BlackRock, Inc.	ADD	6,251	$68.1K
BANK OF AMERICA CORP /DE/	TRIM	17	$185.00
UBS Group AG	NEAR_EXIT	3	$33.00
BANK OF AMERICA CORP /DE/	TRIM	23	$332.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 9, 2026

Earnings date

EXOZ Q3 2026 Earnings Scheduled — 2026-11-09

Recent

Oct 16, 2026

Trading halt

Halt Resumed: EXOZ — trading resumed after LUDP (Volatility Trading Pause)

Halted 2026-10-16T16:00:55.000Z | Resumed 2026-10-16T16:05:55.000Z

Oct 16, 2026

Trading halt

Trading Halt: EXOZ — LUDP (Volatility Trading Pause)

eXoZymes Inc. Cmn Stk | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

Aug 25, 2026

Trading halt

Halt Resumed: EXOZ — trading resumed after LUDP (Volatility Trading Pause)

Halted 2026-08-25T19:52:26.000Z | Resumed 2026-08-25T20:00:00.000Z

Aug 25, 2026

Trading halt

Trading Halt: EXOZ — LUDP (Volatility Trading Pause)

eXoZymes Inc. Cmn Stk | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

Aug 10, 2026

Earnings date

EXOZ Q2 2026 Earnings Scheduled — 2026-08-10

Insider ledger

Form 4

$6.4K

bought · 1 insider

$15.4K

sold · 1 insider · excl. 1 subscriber-only trade

−49.9%

vs their $7.49 cost

Date	Insider	Type	Value
Oct 12, 2026	🔒 Fresh data, subscribers only	SELL
Oct 9, 2026	🔒 Fresh data, subscribers only	EXERCISE
Oct 1, 2026	Rayo Edgardo Javier Director	AWARD	25,000 sh
Oct 1, 2026	MARLETT CHRISTOPHER A Director	AWARD	10,000 sh
Oct 1, 2026	Lalonde James Joseph Director	AWARD	10,000 sh
Oct 1, 2026	DIGIANDOMENICO ANTHONY Director	AWARD	10,000 sh
Oct 1, 2026	Bowie James Ulrich Director	AWARD	10,000 sh
Oct 1, 2026	BELL LON E Director	AWARD	10,000 sh